Physician profile
Stephen N Marks
NPI 1437120235
$14,239.02
in general payments reported to CMS, 2019-2025
34 companies · $3,098 in 2025
The $3,098 reported for 2025 was more than what 80% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $735 · 2021: $1,077 · 2022: $2,543 · 2023: $2,335 · 2024: $2,862 · 2025: $3,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,972 · Consulting Fee: $290 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,972.00 |
| Consulting Fee | $289.65 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,215.40 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,879.23 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $975.67 | 2022-2025 | Tezspire |
| Genzyme Corporation | $917.68 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $819.82 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Adma Biomanufacturing LLC | $800.63 | 2021-2025 | |
| Genentech USA, INC. | $568.03 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $555.14 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $544.94 | 2022-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $381.84 | 2019-2025 | Dupixent |
| Genentech, INC. | $381.39 | 2022-2025 | Xolair |
| Shire North American Group INC | $239.37 | 2019 | |
| Csl Behring | $232.00 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $198.89 | 2020-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $193.03 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $179.45 | 2021-2023 | Actimmune |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.63 | 2019-2020 | |
| Pfizer INC. | $160.81 | 2020-2025 | |
| Verona Pharma, INC. | $145.24 | 2025 | Ohtuvayre |
| Octapharma USA, INC. | $120.37 | 2021-2024 | Panzyga |
| Optinose US, INC. | $67.20 | 2020-2022 | |
| Pharming Healthcare, INC. | $66.54 | 2024-2025 | Ruconest |
| Lilly USA, LLC | $65.72 | 2024 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $52.94 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $48.33 | 2025 | Neffy |
| Abbvie INC. | $44.61 | 2022-2023 | |
| Philips North America LLC | $40.59 | 2021-2023 | |
| Alk-Abello, INC | $38.11 | 2021-2024 | Grastek, Odactra, Ragwitek |
| Kaleo, INC. | $32.19 | 2021 | |
| Leo Pharma INC. | $27.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.76 | 2021 | |
| Organon LLC | $20.05 | 2025 | |
| Cycle Pharmaceuticals INC | $16.39 | 2025 | Sajazir |
| Sunovion Pharmaceuticals INC. | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.